OneSource receives USFDA EIR with VAI classification for Bengaluru sterile facility
OneSource Specialty Pharma received the USFDA Establishment Inspection Report with a 'Voluntary Action Indicated' (VAI) classification for its Sterile Product Division facility in Bengaluru.
By ScoutQuest · · 1 min read
- USFDA Inspection Outcome
- Voluntary Action Indicated (VAI) classification
- Inspection Period
- June 22 to June 30, 2026
- Facility Inspected
- Sterile Product Division facility in Bengaluru
- Release
- Press release
🏭 Managing Director and CEO Neeraj Sharma said the inspection outcome reflects the company's commitment to quality, regulatory compliance and operational excellence, and that the SPD facility plays an integral role in its sterile manufacturing capabilities.
📌 The company says the development adds to its regulatory track record as it builds a CDMO platform spanning four modalities: drug-device combination, biologics, sterile injectables and soft gelatin capsules.
Also from Onesource Specialty Pharma
OneSource Specialty Pharma CEO Neeraj Sharma discussed Q2 results and growth drivers including semaglutide supplies to Dr Reddy's for Canada, biologics and a new cartridge line
29 Oct 2026
OneSource Specialty Pharma makes audio recording of Q2 FY27 earnings call held October 27, 2026 available
27 Oct 2026
OneSource Specialty shares surged more than 13% on heavy volume following Q2 results
27 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.